Back
Arrowhead Pharmaceuticals Vs. Alnylam Pharmaceuticals Industry Stock Comparison
Sell
20
ARWR
Arrowhead Pharmaceuticals
Last Price:
21.14
Seasonality Move:
6.36%
Sell
27
ALNY
Alnylam Pharmaceuticals
Last Price:
276.54
Seasonality Move:
5.61%
Sell
20
Arrowhead Pharmaceuticals (ARWR)
is a Sell
Is Arrowhead Pharmaceuticals a Buy, Sell or Hold?
- The current Arrowhead Pharmaceuticals [ARWR] share price is $20.78. The Score for ARWR is 20, which is 60% below its historic median score of 50, and infers higher risk than normal.
- ARWR is currently trading in the 10-20% percentile range relative to its historical Stock Score levels.
- This Score is currently showing an extreme reading that indicates risk could be especially high.
Sell
27
Alnylam Pharmaceuticals (ALNY)
is a Sell
Is Alnylam Pharmaceuticals a Buy, Sell or Hold?
- The current Alnylam Pharmaceuticals [ALNY] share price is $273.15. The Score for ALNY is 27, which is 46% below its historic median score of 50, and infers higher risk than normal.
- ALNY is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
ARWR Stock Price Chart
What is Arrowhead Pharmaceuticals's stock price today?
-
The Arrowhead Pharmaceuticals share price today is $20.78
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and ARWR is experiencing slight buying pressure.
ALNY Stock Price Chart
What is Alnylam Pharmaceuticals's stock price today?
-
The Alnylam Pharmaceuticals share price today is $273.15
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and ALNY is experiencing slight selling pressure.
ARWR Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -1.2 | Sell |
| Relative Strength Index (14 RSI): | 38.46 | Sell |
| Chaikin Money Flow: | 358727 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (21.28 - 24.28) | Sell |
| Bollinger Bands (100): | (22.65 - 26.99) | Sell |
ALNY Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 2.49 | Buy |
| Relative Strength Index (14 RSI): | 58.43 | Buy |
| Chaikin Money Flow: | -281455 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (256.46 - 277.82) | Buy |
| Bollinger Bands (100): | (163.13 - 268.55) | Buy |
ARWR Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 20.89 | Sell |
| 20-day SMA: | 22.72 | Sell |
| 50-day SMA: | 24.98 | Sell |
| 200-day SMA: | 27.23 | Sell |
| 8-day EMA: | 21.06 | Sell |
| 20-day EMA: | 22.26 | Sell |
| 50-day EMA: | 23.83 | Sell |
| 200-day EMA: | 26.5 | Sell |
ALNY Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 264.5 | Buy |
| 20-day SMA: | 266.49 | Buy |
| 50-day SMA: | 259.42 | Buy |
| 200-day SMA: | 191.14 | Buy |
| 8-day EMA: | 267.08 | Buy |
| 20-day EMA: | 264.76 | Buy |
| 50-day EMA: | 252.59 | Buy |
| 200-day EMA: | 207.34 | Buy |
Arrowhead Pharmaceuticals Earnings Growth & ARWR Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.51 per share, an increase next quarter of $0.05 per share, a decrease this year of $3.09 per share, and an increase next year of $0.08 per share.
Alnylam Pharmaceuticals Earnings Growth & ALNY Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.57 per share, an increase next quarter of $0.47 per share, an increase this year of $1.30 per share, and an increase next year of $0.57 per share.
Arrowhead Pharmaceuticals Technical Analysis
| Sep 5 | Sep 6 | Sep 9 | Sep 10 | Sep 11 | Sep 12 | Sep 13 | Sep 16 | Sep 17 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep | ||||||||||
| 05 | 06 | 09 | 10 | 11 | 12 | 13 | 16 | 17 | 18 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Alnylam Pharmaceuticals Technical Analysis
| Sep 5 | Sep 6 | Sep 9 | Sep 10 | Sep 11 | Sep 12 | Sep 13 | Sep 16 | Sep 17 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep | ||||||||||
| 05 | 06 | 09 | 10 | 11 | 12 | 13 | 16 | 17 | 18 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||